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        The ability to breathe depends on oxy-
gen exchange in the alveoli of the lung. 
Surfactant, which is composed of phos-
pholipids and surfactant proteins (SPs), 
is essential to reduce surface tension at 
the air  –  fl  uid interface, thereby prevent-
ing pulmonary collapse and facilitating 
oxygen exchange. Both SPs and surfac-
tant lipids are produced by alveolar type 
II epithelial cells. Hydrophobic SP-B 
and SP-C are assembled, along with 
phospholipids, into intracellular lamel-
lar bodies, whereas hydrophilic SP-A 
and SP-D are released through secre-
tory vesicles. Breathing triggers the re-
lease of the lamellar body contents into 
a thin aqueous layer covering the alve-
oli, with the polar heads of the phos-
pholipids facing the fl  uid, and their 
hydrophobic tails facing the air. Surfac-
tant homeostasis is maintained by the 
uptake and recycling of surfactant ag-
gregates by alveolar type II epithelial cells, 
and by the internalization and intracel-
lular catabolism by alveolar macrophages. 
This homeostatic turnover is critical, as 
accumulation of surfactant can impair 
oxygen uptake by the lung. 
  GM-CSF has emerged as an es-
sential factor in maintaining alveolar 
homeostasis by promoting surfactant ca-
tabolism by alveolar macrophages, such 
that appropriate levels of surfactant are 
maintained in the alveolar space. GM-
CSF, also known as colony-stimulating 
factor 2 (CSF2), is produced by T cells 
and macrophages after activation, and 
can also be produced by other cell types 
(such as endothelial cells and fi  bro-
blasts) after stimulation with TNF-    , 
interleukin (IL)-1, IL-2, and interferon 
(IFN)-    . GM-CSF was originally iden-
tifi  ed by its ability to induce proliferation 
and diff  erentiation of myeloid progeni-
tor cells in vitro, but subsequent studies 
have shown that it can modulate the 
function of many cell types, including 
mature monocytes, neutrophils, eosin-
ophils, basophils, DCs, invariant natu-
ral killer T (iNKT) cells, endothelial 
cells, and neuronal cells. GM-CSF also 
regulates placental function (for a re-
cent review on GM-CSF see [  1  ]). All 
GM-CSF  –  responsive cells express the 
heterodimeric GM-CSF receptor (GM-
CSFR), which is composed of the ligand-
binding     chain (encoded by the  CSF2RA   
gene), and the signal-transducing      
chain (encoded by the   CSF2RB   gene); 
the latter is also shared by the IL-3 and 
-5 receptors. Surprisingly, disruption 
of   csf2   (encoding GM-CSF) or   csf2rb   
in mice does not impair steady-state 
hematopoiesis, but triggers a progres-
sive PAP-like lung disease with accu-
mulation of surfactant lipids and proteins 
in the alveolar space (  2, 3  );   csf2ra  -defi  -
cient mice have not yet been developed. 
In this issue, two groups of investiga-
tors independently report that mutations 
in the   CSF2RA   gene in humans result 
in PAP (  4, 5  ). 
  The biology of PAP 
  PAP comprises a heterogeneous group 
of rare disorders in which surfactant lip-
ids and proteins, lymphocytes, and large, 
foamy alveolar macrophages accumu-
late within the alveoli, often leading 
to reduced oxygen uptake (ventilation-
perfusion disturbance) and severe re-
strictive lung disease (  6  ) PAP is usually 
secondary to the formation of anti  –
  GM-CSF neutralizing autoantibodies 
(  7  ), but can also be associated with mu-
tations in the genes encoding SP-B or 
SP-C (  8  ), as well as a variety of condi-
tions that aff  ect the function of alveo-
lar macrophages, including hematologic 
malignancies, autoimmunity, infections, 
inhalation of silica or other toxic mate-
rial, and the use of immunosuppressive 
drugs (  6  ). 
  Observations in humans and mice 
support a critical role for perturbed 
GM-CSFR signaling in the pathophysi-
ology of PAP. In mice, ablation of   csf2   or 
  csf2rb   resulted in intra-alveolar accumu-
lation of lipoproteinaceous material and 
foamy macrophages (  2, 3  ). Neither de-
letion aff  ected the synthesis and secretion 
of SPs, but both severely perturbed sur-
factant catabolism (  9  ). Expressing GM-
CSF in the lungs (  10  ) or administering 
recombinant GM-CSF (  11  ) rescued 
the disease phenotype of   csf2 
    /        mice, 
whereas bone marrow transplantation 
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other, as well as the      chain itself (  Fig. 1  ).   
These phosphorylation events trigger 
the recruitment and phosphorylation of 
STAT5. Eventually, several GM-CSF 
target genes are activated, including the 
gene encoding the transcription factor 
PU.1, which controls terminal matura-
tion of alveolar macrophages by up-regu-
lating the expression of CD32, mannose 
receptor, and macrophage CSF recep-
tor (M-CSFR). Accordingly, the ex-
pression of PU.1 and of PU.1-dependent 
proteins is markedly reduced in   csf2 
    /        
mice, resulting in reduced macrophage 
adhesion, phagocytosis, and microbici-
dal activity (  17  ). Similar observations 
have been reported in alveolar macro-
phages from patients with PAP (  18  ). 
Although the expression profi  le of diff  er-
entiation markers on neutrophils from pa-
tients with autoantibody-mediated PAP 
is normal, these cells show impaired func-
tion in vitro after GM-CSF priming (  19  ). 
  Leukocytes from the three patients 
reported by Suzuki et al. and Martinez-
Moczygemba et al. failed to up-regulate 
CD11b in response to GM-CSF. Inter-
estingly, the two siblings in the Suzuki 
et al. study, who carried the G174R mu-
tation, showed markedly reduced GM-
CSF  –  stimulated STAT5 phosphorylation, 
which was partially rescued by concentra-
tions of GM-CSF within the range de-
tected in vivo in patients. It is noteworthy 
that the disease presentation was delayed 
in these two patients, and one was even 
thought to be unaff  ected before this study 
was performed. These fi  ndings raise the 
possibility that hypomorphic mutations in 
  CSF2RA   may result in milder clinical 
forms of the disease and that, in these 
cases, boosting local concentrations of 
GM-CSF via aerosol administration 
might be benefi  cial. The delayed clinical 
presentation and milder phenotype ob-
served in the siblings could also be ex-
plained by an alternative hypothesis (  4  ). It 
has been observed that two residues (S585 
and Y577) in the GM-CSFR      chain act 
as a binary switch that triggers distinct 
downstream events. Low concentrations 
of the cytokine trigger S585 phosphory-
lation, resulting in activation of PI3-
kinase and cell survival, whereas high 
concentrations favor phosphorylation of 
Y577 and JAK2 activation, resulting in 
was found to carry an internal deletion 
in the PAR1 region encompassing exons 
5  –  13 of the   CSF2RA   gene, which pre-
vented the expression of GM-CSFR     
on the surface of circulating monocytes. 
The patient ’  s father and sibling, who were 
reportedly healthy, had two populations 
of monocytes, one that expressed GM-
CSFR     and one that did not. This ob-
servation is diffi   cult to reconcile with the 
notion that the   CSF2RA   gene escapes X 
inactivation, as this would predict that all 
monocytes from individuals heterozy-
gous for null defects should still be able 
to express the protein through the un-
aff  ected allele (although possibly at re-
duced levels). However, recent data 
indicate that the levels of GM-CSFR     
expression in circulating monocytes may 
vary substantially  —  for as yet unknown 
reasons  —  even among healthy subjects 
(  15  ). It is thus possible that the two 
monocyte populations in the patient  ’  s 
father and sibling represented monocytic 
cells at diff  erent stages of diff  erentiation 
or activation. 
  The two siblings reported by Suzuki 
et al., in contrast, had a normal female 
46, XX karyotype, and their monocytes 
were found to express GM-CSFR     (  5  ). 
Using a combination of molecular and 
cytogenetic studies, the authors showed 
that the maternally derived X chromo-
some carried a 1.6-Mb deletion in PAR1 
that encompassed the   CSF2RA   locus, 
whereas the paternal   CSF2RA   allele 
carried a single nucleotide substitution 
that resulted in an amino acid change 
(G174R) that abolished an N-glycosyl-
ation site. In both articles, functional as-
says confi  rmed that the   CSF2RA   genetic 
lesions disrupted responses to GM-CSF. 
  Mechanics of GM-CSF signaling 
  Recent studies have led to the unex-
pected observation that the high-affi   nity 
GM-CSFR complex assumes a hexa-
meric stoichiometry, with a 2:2:2 ratio 
between GM-CSF and the      and      re-
ceptor chains, and that the assembly of 
two hexamers into a dodecamer is re-
quired for receptor activation and sig-
naling (  16  ). This conformation brings 
two GM-CSFR      chains into close prox-
imity, so that the      chain  –  bound JAK2 
molecules can cross-phosphorylate each 
and retrovirus-mediated   csf2rb   gene trans-
fer into hematopoietic stem cells cor-
rected the defect in   csf2rb 
    /        mice (  3, 12  ). 
These studies demonstrate a primary 
role for alveolar macrophages in GM-
CSF  –  dependent surfactant homeostasis 
in mice. 
  In this issue, Suzuki et al. (p.   2703  ) 
and Martinez-Moczygemba et al. (p. 
  2711      ) describe   CSF2RA   mutations in 
three patients with primary PAP (  4, 5  ). 
These studies, along with the previous 
observations that the majority of pa-
tients with PAP have anti  –  GM-CSF 
autoantibodies (  6  ), and that abnormal-
ities of GM-CSFR     may account for 
some rare congenital forms of the disease 
(  13  ), unequivocally demonstrate a prom-
inent role for GM-CSF in lung homeo-
stasis in humans. 
  These new studies raise several in-
teresting questions. From a genetic stand-
point, the complicated mechanisms 
leading to PAP in the aff  ected patients 
are noteworthy. Unlike the murine 
  csf2ra   gene, which maps in the telomeric 
region of mouse chromosome 19, the 
human   CSF2RA   gene is located in the 
X-Y pseudoautosomal region (PAR1) 
(  14  ). This region, comprising     2.6 Mb 
of homologous sequence between the 
X and the Y chromosomes, is essential 
for a single obligatory recombination 
event to occur during male meiosis. Genes 
contained in the PAR1 region of the X 
chromosome, including   CSF2RA  , escape 
the phenomenon of X chromosome in-
activation. Accordingly, genetic defects 
in these genes might result in a disease 
phenotype because of haploinsuffi   ciency 
or through complex mechanisms that 
also inactivate the other allele. All three 
patients reported by Suzuki et al. and 
Martinez-Moczygemba et al. were fe-
males whose genetic defects aff  ected both 
X chromosomes. 
  The patient described by Martinez-
Moczygemba et al. developed severe 
respiratory distress and failure to thrive 
early in life, as well as symptoms associ-
ated with Turner syndrome (  4  ). She had 
a 46,X,i(Xq) karyotype (one copy of the 
X chromosome was normal and the sec-
ond had a deletion of the short arm and 
a duplication of the long arm), in which 
the apparently normal X chromosome JEM VOL. 205, November 24, 2008  2695
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  il3   gene does not aff  ect steady-state he-
matopoiesis or cause lung disease, but 
reduces mast cell function in response 
to parasitic infections (  22  ). The course of 
the disease in the patient with complete 
loss of   CSF2RA   and   IL3RA   expression 
was too rapid to ascertain whether the 
loss of IL-3  –  mediated signaling might 
have had any clinical consequence. 
  Beyond surfactant 
  The demonstration of   CSF2RA   muta-
tions in patients with primary PAP raises 
important questions regarding the role 
of this signaling pathway beyond sur-
factant homeostasis. Opportunistic in-
fections have been documented in   >  10% 
of PAP patients, and uncontrolled in-
fections are the second most important 
cause of death after respiratory insuf-
fi  ciency (  23  ). Increased susceptibility 
to infections with   Pneumocystis jiroveci  , 
  Listeria monocytogenes  ,   Mycobacterium tu-
berculosis  , adenovirus, and group B strep-
tococcus has been reported in   csf2 
    /        
the wild-type      chain. If so, a mild PAP 
phenotype might result from heterozy-
gous mutations not because of haplo-
insuffi   ciency, but rather because of a 
dominant-negative eff  ect. Although in 
vitro transfection studies may help solve 
this issue, it is important to note that the 
father of the two patients reported by 
Suzuki et al. carries the G174R muta-
tion and is apparently asymptomatic (  5  ). 
Although his serum levels of SP-D were 
in the upper normal range, his leuko-
cytes showed normal uptake of GM-CSF 
and normal GM-CSF  –  induced STAT5 
phosphorylation. Thus, further studies 
are needed to determine if heterozygous 
mutations in the   CSF2RA   gene may 
lead to a disease phenotype. 
  The genetic defect in the patient de-
scribed by Martinez-Moczygemba et al. 
resulted not only in loss of   CSF2RA  , 
but also in the complete loss of the  IL3RA   
gene (  4  ), which maps next to   CSF2RA   
in the PAR1 region and encodes for the 
IL-3R      chain. In mice, ablation of the 
cell proliferation, diff  erentiation and acti-
vation (  20  ). In the presence of high con-
centrations of the ligand, it is possible that 
the G174R mutant      chain could bind 
GM-CSF with suffi   cient avidity to pro-
mote phosphorylation of the      chain 
tyrosine residue, and thus enable partial 
alveolar macrophage function. Further-
more, PU.1 and C/EBP proteins co-
operate to induce GM-CSFR      chain 
expression (  21  ), creating a positive-feed-
back loop that may also help promote 
GM-CSF  –  mediated intracellular signal-
ing in patients with hypomorphic muta-
tions in GM-CSFR components. 
  On the other hand, functional stud-
ies performed in the siblings with the 
G174R      chain mutation showed clear 
abnormalities in GM-CSF  –  mediated sig-
naling. In light of the multimolecular 
complex of the high-affi   nity GM-CSFR 
(  16  ), one might expect that the G174R 
mutant might interfere with GM-CSF  –
  mediated binding and signaling if ex-
pressed at an equimolecular ratio with 
    Figure 1.         Mutations of GM-CSFR     disrupt alveolar macrophage functions and surfactant homeostasis.   (top) (A) GM-CSF binds to GM-CSF 
receptor      (GM-CSFR   ) to form a low-affi  nity complex, which then interacts with the      complex (two      chains constitutively bound to JAK2) to form the 
high-affi  nity hexameric receptor complex (B). Lateral movement and aggregation of two such complexes form the active dodecamer signaling receptor 
(not depicted), allowing cross-phosphorylation of the JAK2 molecules and the      subunit. Activated JAK2 phosphorylates the transcription factors STAT5, 
which then dimerizes and migrates to the nucleus where it induces the expression of the PU.1 transcription factor gene (C). This results in the expression 
of various PU.1-dependent genes and subsequent activation of multiple phagocytic functions, such as adhesion, phagocytosis, killing, signaling through 
TLR4, and the release of IL-12 and -18, which in turn induce release of IFN-     by T and NK cells. This pathway also induces surfactant catabolism (D), al-
though the mechanistic details of this pathway remain to be defi  ned. (bottom) GM-CSF signaling is abrogated in phagocytes from patients with primary 
PAP who fail to express functional GM-CSFR     molecules (E). In these conditions, surfactant is still taken up by the alveolar macrophages, but is not prop-
erly catabolized, leading to progressive surfactant accumulation within the phagocyte (producing the typical foamy appearing alveolar macrophages) and 
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beta IL3 receptor-defi  cient mice are normal.   
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pairment of the ability of macrophages 
and neutrophils to mediate antimicro-
bial functions (for review see [  6  ]). 
  Overall, the two independent ob-
servations of   CSF2RA   mutations leading 
to abnormal GM-CSFR     chain expres-
sion and function further support the 
importance of GM-CSF  –  mediated sig-
naling in surfactant homeostasis, and the 
phenotypic diff  erences observed by the 
two groups demonstrate the complexity 
of this process. These novel clinical fi  nd-
ings will hopefully prompt further basic 
and clinical studies that will lead to a 
better understanding not only of PAP and 
its consequences but also of other path-
ological and physiological processes in-
volving the GM-CSF  –  surfactant axis. 
  Importantly, the observation that PAP 
may be inherited as a Mendelian trait, 
and that mutations of the   CSF2RA   gene 
result in a lung-specifi  c phenotype, make 
PAP an unusual presentation of a pri-
mary immune defi  ciency disorder (PID), 
and thus further broadens the clinical 
defi  nition of PIDs (  28  ). Finally, the fact 
that PAP may be caused either by an 
autoimmune process (with production 
of anti  –  GM-CSF antibodies) or by ab-
normalities of the   CSF2RA   gene pro-
vides yet another example of how PIDs 
may be phenocopied by autoimmune 
processes that abrogate a specifi  c immune 
pathway. This observation is similar to 
reports in patients with increased sus-
ceptibility to mycobacterial diseases 
resulting from genetic defects in the 
IL-12/IL-23  –  IFN-     pathway (  29  ) or 
the production of autoantibodies to 
IFN-     (  30    32  ). 
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